NTRA

Natera is a high-quality, fast-compounding diagnostics franchise. FY2025 revenue hit $2.31B, up 35.9% YoY, the latest leg of a relentless ramp ($625M→$820M→$1.08B→$1.70B→$2.31B over five years). The MD&A grounds that growth in volume, not just price: ~3,525,500 tests processed in 2025 vs ~3,064,600 in 2024, led by Signatera (oncology ctDNA/MRD) layered on the Panorama NIPT and Horizon carrier-screening base. Crucially, operating cash flow turned solidly positive at $215M (+58.7%), so the GAAP losses are increasingly an artifact of heavy reinvestment rather than a cash-burn problem — R&D alone was $624M, up 54.4%, and is the main reason operating income worsened to -$310M (-39.4%). The balance sheet is a fortress for a company this early in its profit curve: $1.08B cash, modest debt (~$80M current + ~$283M long-term), equity of $1.71B and liabilities/equity of just 0.40x. There is no financing risk here.

The problem is price, not quality. At $231.41 the stock trades at 14.2x sales and carries a $32.8B market cap against a business that still posts a -$1.52 diluted EPS, a -13.4% operating margin and a -12.2% ROE. The accumulated deficit sits at -$2.78B. A P/S in the mid-teens already embeds years of continued ~30%+ growth and an eventual march to GAAP profitability; the multiple, not the company, is what limits forward return. Net loss actually widened slightly to -$208M as R&D outran revenue, so the inflection to profitability is being deliberately deferred in favor of share gains in MRD — a reasonable strategy, but one that pushes the payoff out and keeps the valuation reliant on execution.